AroCell Q4: Entering exciting 2021

Redeye gives its comment on AroCell’s Q4 report and views 2021 as exciting, a year which potentially entails significant positive changes to the case – FDA approval of TK210 ELISA. However, this is something we expect to come sometime towards the end of the year.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.